Discovery of a new STING agonist with cancer-fighting effects
Author Information
Author(s): Wang Xiyuan, Zhan Zhengsheng, Wang Zhen, Zhang Yan, Zhao Kaiyan, Li Han, Zhou Xiaoqian, Guo Yuting, Fan Fengying, Ding Jian, Geng Meiyu, Yu Xuekui, Duan Wenhu, Xie Zuoquan
Primary Institution: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Hypothesis
Can a non-nucleotide STING agonist provide systemic antitumor effects?
Conclusion
The non-nucleotide STING agonist DW18343 shows strong antitumor effects and activates immune responses.
Supporting Evidence
- DW18343 activates various STING isoforms and triggers immune responses.
- It shows broad antitumor effects in multiple mouse tumor models.
- The compound induces immune memory to prevent tumor recurrence.
Takeaway
Scientists created a new medicine called DW18343 that helps the body fight cancer by boosting the immune system.
Methodology
The study involved developing a new STING agonist, testing its effects on immune cells and tumor models in mice.
Limitations
The study did not explore the optimal administration method or potential drug combinations.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website